TPG and Par plan $1.9bn wedding (unless a sugar daddy comes along)
This article was originally published in Scrip
Executive Summary
Private investment firm TPG will pay $1.9 billion or $50 per share to acquire Par Pharmaceutical – a 37% premium over the generics manufacturer's 13 July stock price, unless Par can attract a stronger suitor within the next six weeks. The company's stock price shot up 36.7% to $50, a level unseen since early 2004.